US legislation targets China pharma IP licensing following multi-billion Pfizer, BMS deals

Novo NordiskNovo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - simplywall.st

MKS NewportCenters Receive Awards for Nanoscale Research | light speed | Feb 2002 - Photonics Spectra

EurofinsEurofins Scientific SE Stock (FR0014000MR3): stock in focus after quiet trading week - AD HOC NEWS

CellMechanism of lipid transfer by bridge-like protein VPS13A and the scramblase XK

CellGregory J. Hannon (1964–2026)

FierceBiotechLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - investor.lilly.com

Eli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - PR Newswire

Eli LillyLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ - Fierce Biotech

Eli LillyAbridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion - Healthcare Dive

Endpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and more

Clinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare Diseases